Chimeric antigen receptor-modified T cells derived from defined CD8(+) and CD4(+) subsets confer superior antitumor reactivity in vivo

Adoptive T-cell therapy with gene-modified T-cells expressing a tumor-reactive T-cell receptor (TCR) or chimeric antigen receptor (CAR) is a rapidly growing field of translational medicine and has shown success in the treatment of B-cell malignancies and solid tumors. In all reported trials, patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommermeyer, Daniel, Hudecek, Michael, Kosasih, Paula L., Gogishvili, Tea, Maloney, David G., Turtle, Cameron J., Riddell, Stanley R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746098/
https://www.ncbi.nlm.nih.gov/pubmed/26369987
http://dx.doi.org/10.1038/leu.2015.247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746098/
https://www.ncbi.nlm.nih.gov/pubmed/26369987
http://dx.doi.org/10.1038/leu.2015.247

Ejemplares similares